TCR-engineered T Cells in Solid Tumors: IMA202-101

Inclusion Criteria: * Pathologically confirmed advanced and/or metastatic solid tumor * Patients may enter screening procedure before, during, or after the last available indicated standard of care treatment. There is no limitation for prior anti cancer treatments. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * HLA phenotype positive for the study * Measurable disease and accessible to biopsy * Adequate pulmonary function per protocol * Acceptable organ and bone marrow function per protocol * Acceptable coagulation status per protocol * Adequate hepatic function per protocol * Adequate renal function per protocol * Patient's tumor must express tumor antigen by qPCR using a fresh tumor biopsy specimen * Life expectancy more than 3 months * Confirmed availability of production capacities for IMA202 product * Patients must have recurrent/progressing and/or refractory solid tumors and must have received or not be eligible for all available indicated standard of care treatment. * For hepatocellular carcinoma (HCC) patients only, Child-Pugh score of ≤ 6 * IMA202 product must have passed all of the release tests * Female patient of childbearing potential must use adequate contraception prior to study entry until 12 months after the infusion of IMA202 * Male patient must agree to use effective contraception or be abstinent while on study and for 6 months after the infusion of IMA202 * Hepatocellular carcinoma (HCC) patients with liver cirrhosis only - upper endoscopy is required within 6 months of study entry * The patient must have recovered from any side effects of prior therapy to Grade 1 or lower (except for non-clinically significant toxicities; e.g., alopecia, vitiligo) prior to lymphodepletion. As determined by the investigator, the patient may still be eligible if the patient has not fully recovered from Grade ≥ 2 toxicities if these toxicities are not anticipated to further improve (e.g., chronic neuropathy) and such toxicities are not anticipated to worsen with the lymphodepletion therapy Exclusion Criteria: * History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years * Solid tumors with low likelihood of tumor biomarker expression per protocol * Pregnant or breastfeeding * Serious autoimmune disease Note: At the discretion of the investigator, these patients may be included if their disease is well controlled without the use of immunosuppressive agents. * History of cardiac conditions as per protocol * Prior stem cell transplantation or solid organ transplantation * Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study * History of hypersensitivity to cyclophosphamide (CY), fludarabine (FLU), IL-2, or any of the rescue medications * History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician * HIV infection, active hepatitis B virus (HBV), active hepatitis C virus (HCV) infection, ongoing active anti-HCV treatment or detectable HBV or HCV viral load at the most recent laboratory report. Patients with both HBV and HCV infections will be excluded from screening 1. Patients with a history of HCV infection and with an undetectable viral load per the most recent laboratory report and/or completed anti-HCV treatment but are HCV antibody positive are permitted. 2. History of treated HBV infection is permitted if the viral load is undetectable per the most recent laboratory report. Note: HCC patients with controlled HBV infection, as defined by resolved (anti-hepatitis B surface antigen \[HBs-Ag\] antibody (Ab) negative, anti-core antigen \[HBc Ag\] Ab positive) or chronic stable (anti HBs-Ag Ab positive) HBV infection will be eligible for screening. Patients with active HBV infection who are not on anti-HBV treatment will be excluded. * Any condition contraindicating leukapheresis, lymphodepletion, low-dose IL-2, and/or IMA202 treatment * Patients with any active viral infection * Patients with active brain metastases NOTE: Patients with a history of brain metastases may be eligible, if an imaging scan with contrast enhancement not older than 4 weeks is able to exclude the existence of currently active brain metastasis, and steroid therapy has been discontinued for ≥2 weeks. * Treatment with protocol-defined excluded treatments, medical devices, and/or procedures per protocol * Concurrent participation in an interventional part of another clinical trial.